Prenetics Leadership Buys $1.3M Shares, Raising Insider Stake to $2.75M
Prenetics executives acquired 76,060 shares for $1.301 million at an average of $17.11 per share during the week of February 23–27, 2026. This round follows November’s $1.45 million purchases, bringing the cumulative personal investment to $2.75 million across two consecutive post-earnings open trading windows.
1. Second Consecutive Post-Earnings Stock Purchases
During February 23–27, 2026, Prenetics executives acquired 76,060 common shares at an aggregate cost of approximately $1.301 million, averaging $17.11 per share in the open trading window following fourth-quarter and full-year 2025 results.
2. Executive Transaction Details
Chief Executive Officer Danny Yeung purchased 42,282 shares for about $750,000 at an average of $17.71, Chief Financial Officer Stephen Lo acquired 15,603 shares for roughly $250,000 at $16.00 each, Chief Marketing Officer Rahul Ramchand bought 15,000 shares for $251,000 at $16.76 apiece, and Americas President David Vanderveen added 3,175 shares for $50,000 at $16.27 per share.
3. Cumulative Insider Investment Totals $2.75M
Combined with approximately $1.45 million of share purchases made in November 2025, the leadership team’s personal stake now totals about $2.75 million across two consecutive post-earnings open market acquisitions.
4. Management Confidence and Outlook
Management underscores strengthening IM8 brand fundamentals, noting $100 million in annualized recurring revenue and expanding global distribution, and believes the current share price undervalues the company’s growth trajectory.